Clinical Trial Update: A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial update evaluating safety, efficacy, and pharmacokinetics of WJ01024 tablets in combination with ruxolitinib for intermediate- and hig…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)
• WJ01024

Snippet

Sponsor: Suzhou Junjing BioSciences Co., Ltd. | Conditions: Intermediate- and High-risk Myelofibrosis (MF) Patients With Splenomegaly | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING